TEL AVIV, Israel, February 5, 2013 /PRNewswire/ -- Elbit Imaging Ltd. ("EI"or the"Company") (TASE, NASDAQ: EMITF) announced today, that Standard & Poor's Maalot, has decided to change the rating of all of the Company's Series A through Series G Notes and Series 1 Notes, which are traded on the Tel Aviv Stock Exchange, from an "'ilB/Negative" credit rating, to an "'ilCC/Watch Negative' credit rating on credit watch. About Elbit Imaging Ltd. Elbit Imaging Ltd. operates in the following principal fields of business: (i) Commercial and Entertainment Centers - Initiation, construction and sale of shopping and entertainment centers and other mixed-use real property projects, predominantly in the retail sector, located in Central and Eastern Europe and in India, primarily through its subsidiary Plaza Centers N.V. In certain circumstances and depending on market conditions, we operate and manage commercial and entertainment centers prior to their sale; (ii) U.S. Real Property - Investment in commercial real property in the United States; (iii) Hotels - Hotel operation and management; (iv) Medical Industries - (a) research and development, production and marketing of magnetic resonance imaging guided focused ultrasound treatment equipment and (b) development of stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine; (v) Residential Projects - Initiation, construction and sale of residential projects and other mixed-use real property projects, predominately residential, located primarily in India; (vi) Fashion Apparel - Distribution and marketing of fashion apparel and accessories in Israel; and (vii) Other Activity - venture capital investments. Any forward-looking statements in our releasesinclude statements regarding the intent, belief or currentexpectations of Elbit Imaging Ltd. and our management about our business, financial condition, results of operations, and its relationship with its employees and the condition of our properties. Words such as"believe," "expect," "intend," "estimate" and similar expressionsare intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Actual results may differ materially from those projected, expressed or implied in the forward-looking statements as a result of various factors including, without limitation, the factors set forth in our filings with the Securities and Exchange Commission including, without limitation, Item 3.D of our annual report on Form 20-F for the fiscal year ended December 31, 2011, under the caption "Risk Factors." Any forward-looking statements contained in our releases speak only as of the date of such release, and we cautionexisting and prospectiveinvestors not to place undue reliance on such statements. Such forward-looking statements do not purport to be predictions of future events or circumstances, and therefore, there can be no assurance that any forward-looking statement contained our releases will prove to be accurate. We undertake no obligation to update or revise any forward-looking statements.For Further Information:Company Contact:Shimon Yitzhaki Chairman of the Board of Directors Tel: +972-3-608-6048 firstname.lastname@example.orgInvestor Contact:Mor Dagan Investor Relations Tel: +972-3-516-7620 email@example.com SOURCE Elbit Imaging Ltd.
Elbit Imaging (EMITF) is rocketing higher on Tuesday after announcing its Gamida Cell Ltd, which Elbit's subsidiary Elbit Medical Technologies holds 30.8% voting power in, had received an acquisition proposal from a pharmaceutical company.